Retinal implants with wireless microchip restore functional vision in retinitis pigmentosa patients, research finds

February 20, 2013

(Medical Xpress)—Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), announced results from part of its multicentre study were published today in the peer-reviewed journal Proceedings of the Royal Society B. The research found that, during the course of a three to nine month observation period, functional vision was restored in the majority of nine German patients implanted with a subretinal microchip as part of the first module of the Company's second human clinical trial. In addition, visual acuity for two of the nine patients surpassed the visual resolution of patients from the Company's first human clinical trial.

The study titled " with Wirelessly Powered Subretinal Electronic Implant Alpha IMS" was led by researchers at University Eye Hospital in Tubingen, Germany including Professor Eberhart Zrenner and Katarina Stingl, M.D. Patients were implanted with Retina Implant AG's subretinal wireless 3x3 mm2, 1500 pixel Alpha IMS and are able to adjust the level of stimulation received to view objects at varied distances. Of the nine patients observed in the study, three patients were able to read letters spontaneously. During observation in and outside the laboratory patients also reported the ability to recognize faces, distinguish objects such as telephones and read signs on doors.

"The results of our first human clinical trial exceeded our expectations, and we are further encouraged by the results from the second human trial," said Professor Eberhart Zrenner, M.D., lead clinical trial investigator, Institute for Ophthalmologic Research at University Eye Hospital Tuebingen, Germany. "As physicians, we are constantly seeking out the best treatment options for our most in-need patients, which most definitely includes those suffering from advanced-stage retinitis pigmentosa. This research provides additional evidence that our subretinal implant technology can help some patients with retinal degeneration regain functional vision and does so in a way that does not require externally visible equipment."

"The continuation of our trial and publication of this module is the next milestone in our quest to secure CE mark approval and provide RP patients living in darkness with a treatment option," said Walter-G Wrobel, president and CEO, Retina Implant AG. "We are continually humbled by the 36 patients we've implanted thus far and their willingness to participate in this ground-breaking research."

The Company's first clinical trial began in Germany in 2005, where 11 patients suffering from retinitis pigmentosa were implanted with a subretinal microchip below the retina in the macular region. Results from the first trial were published in November 2010 in , concluding that the implantation of Retina Implant's microchip was successful in restoring useful vision in patients previously blind due to retinitis pigmentosa. The second clinical trial with a wireless device that allows patients to use the implant outdoors and at home began in May 2010 in Tuebingen, Germany, and has since expanded into the multicentre phase of the trial with implants taking place in Hong Kong and the UK.

"As a leading relevant patient organisation in the UK we have been watching Retina Implant AG's research with great interest," said David Head, CEO of RP Fighting Blindness. "The results published today show definite promise to one day restore functional vision to patients with advanced-stage ."

Explore further: First blind patients in the UK has retina implant

Related Stories

First blind patients in the UK has retina implant

May 3, 2012
Retina Implant AG, the developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), announced that the first UK patients participating in the Company's multi-centre trial have been successfully implanted. ...

FDA recommends approval for Second Sight's Argus II retinal prosthesis system in the US

October 3, 2012
On Friday September 28, a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel unanimously voted 19-0 that the probable benefit of the Argus II Retinal Prosthesis System outweighs the risks to health, ...

Recommended for you

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

Genetic treatment for blindness may soon be reality

November 11, 2017
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting ...

Study finds donor corneas can be safely preserved for longer period

November 10, 2017
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of ...

Exploring the genetics of glaucoma and retinal development

November 10, 2017
Guillermo Oliver, PhD, the Thomas D. Spies Professor of Lymphatic Metabolism, recently published two studies related to the eye, one on retinal formation and the other on the genetics behind glaucoma.

Scientists discover potential treatment to stop glaucoma in its tracks

November 6, 2017
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, ...

New focus on correcting refractive vision

October 25, 2017
While doctors take delight in solving the common issue of refractive vision error by prescribing eye glasses, Flinders University researchers have found that many patients are upset with this solution and claim it affects ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.